Liquid products nasal spray

Its contract manufacturing is categorized in two different areas (i) topical compositions, which resemble traditional creams, lotions, and ointments in appearance and use, and (ii) liquid compositions that can be absorbed sublingually, nasal spray products, or liquid ingestion products. 

Over the years it has been interesting to note that many compounded products eventually become commercially available products. Recent examples might include fentanyl lozenges, minoxidil topical solution, nystatin lozenges, clindamycin topical solution, tetracaine-adrenalin-cocaine (TAG) solution, dihydroergotamine mesylate nasal spray, buprenorphine nasal spray, buffered hypertonic saline solution, and erythromycin topical solution as well as numerous other dermatological and pediatric oral liquids and some... 

The inclusion of the a routine microbial limit test in a marketed product stability protocol depends on the pharmaceutical dosage form. Typically, the test would be used only for nonsterile products, especially oral liquids, nasal sprays, and topical liquids, lotions, and creams that have sufficient water activity to support the growth of microorganisms. In contrast, tablets, powder- and liquid-filled capsules, topical ointments, vaginal and rectal suppositories, nonaqueous liquids and inhalation aerosols with a water activity too low to allow for the product to support the growth of microorganisms would not be routinely tested. 

In case of the squeeze spray bottle (LDPE) the nasal spray fluid is sprayed by squeezing the bottle. The administered dose depends on the squeezing force and the level of the liquid in the bottle. Because of inaccurate dosing, these bottles are not suitable for the administration of highly active medicinal products. When using the simple squeeze bottle there is a chance the spray fluid gets contaminated with nasal mucus. The patient has to keep the bottle squeezed in until it is removed from the nose. 

---